Despite the fact that BRAF inhibitors have a high response rate in BRAF V600 mutant melanoma, and non-small cell lung cancer, their efficacy as monotherapy in BRAF V600E CRC is limited [36]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.